JAK AND PI3K SIGNALING PATHWAY MARKETS
|
|
- Jacob Black
- 5 years ago
- Views:
Transcription
1 JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com
2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY OBJECTIVES 2 REASONS FOR DOING THIS STUDY 2 CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3 SCOPE OF THE STUDY 3 METHODOLOGY 3 INFORMATION SOURCES 3 ABOUT THE AUTHOR 4 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH WEBSITE 5 DISCLAIMER 5 CHAPTER 2 EXECUTIVE SUMMARY 7 SUMMARY TABLE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS) SUMMARY FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), ) ($ MILLIONS) 8 8 CHAPTER 3 OVERVIEW 11 JANUS KINASE (JAK) AND PHOSPHOINOSITIDE 3-KINASES (PI3K) 11 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS FOR JAK AND PI3K 11 MECHANISM OF ACTION 12 Janus Kinase Therapies/Inhibitors 12 Phosphoinositide 3-kinases (PI3K) Therapies/Inhibitors 12 APPROVED HISTONE DEACETYLASE INHIBITORS 12 CLASSIFICATION 13 JANUS KINASE (JAK) 13 TABLE 1 CLASSIFICATION OF JANUS KINASE (JAK) 13 PHOSPHOINOSITIDE 3-KINASES (PI3K) 13 TABLE 2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K) 14 JANUS KINASE THERAPIES/INHIBITORS 14 Ruxolitinib (INC424/INCB18424) 15 FIGURE 1 STRUCTURE OF INC424 (RUXOLITINIB) 15 Tofacitinib (CP-690,550) 15 FIGURE 2 STRUCTURE OF CP-690,550 (TOFACITINIB) 16 Baricitinib (INC28050/LY ) 16 FIGURE 3 STRUCTURE OF BARICITINIB (INC28050/LY ) 16 NS Momelotinib (CYT-387) 17 FIGURE 4 STRUCTURE OF MOMELOTINIB (CYT-387) 17 AT FIGURE 5 STRUCTURE OF AT Pacritinib (SB1518) 18 FIGURE 6 STRUCTURE OF PACRITINIB (SB1518) 18 LY FIGURE 7 STRUCTURE OF LY
3 TG (SAR302503) 19 FIGURE 8 STRUCTURE OF TG (SAR302503) 19 BMS FIGURE 9 STRUCTURE OF BMS Lestaurtinib (CEP-701) 20 FIGURE 10 STRUCTURE OF LESTAURTINIB (CEP-701) 20 LS WP FIGURE 11 STRUCTURE OF WP AG FIGURE 12 STRUCTURE OF AG AZD FIGURE 13 STRUCTURE OF AZD INCB INCB PHOSPHOINOSITIDE 3-KINASES (PI3K) THERAPIES/INHIBITORS 23 Wortmannin 24 FIGURE 14 STRUCTURE OF WORTMANNIN 24 Perifosine (KRX-0401) 25 FIGURE 15 STRUCTURE OF PERIFOSINE (KRX-0401) 25 LY FIGURE 16 STRUCTURE OF LY Idelalisib (GS-1101, CAL-101) 26 FIGURE 17 STRUCTURE OF IDELALISIB (GS-1101, CAL-101) 26 PX FIGURE 18 STRUCTURE OF PX IPI FIGURE 19 STRUCTURE OF IPI BKM FIGURE 20 STRUCTURE OF BKM Copanlisib (BAY ) 29 FIGURE 21 STRUCTURE OF COPANLISIB (BAY ) 29 PF (PKI-587) 29 FIGURE 22 STRUCTURE OF PF (PKI-587) 30 Pictilisib (GDC-0941) 30 FIGURE 23 STRUCTURE OF PICTILISIB (GDC-0941) 30 Dactolisib (BEZ235) 31 FIGURE 24 STRUCTURE OF DACTOLISIB (BEZ235) 31 Apitolisib (GDC-0980) 31 FIGURE 25 STRUCTURE OF APITOLISIB (GDC-0980) 31 ZSTK FIGURE 26 STRUCTURE OF ZSTK SAR (XL765) 32 FIGURE 27 STRUCTURE OF SAR (XL765) 33 SAR (XL147) 33 FIGURE 28 STRUCTURE OF APITOLISIB SAR (XL147) 33 BYL719 34
4 FIGURE 29 STRUCTURE OF APITOLISIB BYL SIGNAL TRANSDUCTION BIOMARKERS FOR JAK AND PI3K 34 PROSPECTIVE DISEASE TARGETS FOR JAK AND PI3K THERAPIES 35 TABLE 3 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS 36 CHAPTER 4 REGULATORY ASPECTS 42 RUXOLITINIB (INC424) 43 DOSING INFORMATION 43 Dose Modifications 43 SAFETY INFORMATION 43 Safety of Ruxolitinib in Specific Population 44 RISK OF INFECTION 45 Tuberculosis 45 Progressive Multifocal Leukoencephalopathy (PML) 45 Herpes Zoster 45 TOFACITINIB (CP-690,550) 45 DOSING INFORMATION 45 Dose Modifications 45 SAFETY INFORMATION 46 Safety of Tofacitinib in Specific Populations 46 RISK OF INFECTION 47 Tuberculosis 47 REGULATORY DEVELOPMENTS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS 47 CHAPTER 5 NEW DEVELOPMENTS 50 NEW DEVELOPMENTS 50 TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS TABLE 6 NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY COLLABORATIVE TRIALS AND FUTURE ACTIVITIES CHAPTER 6 MARKET ANALYSIS-SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) 70 MARKET BY THE TYPE 71 TABLE 7 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS) FIGURE 30 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, RUXOLITINIB (INC424, INCB18424)-JANUS KINASE (JAK) INHIBITOR 72 Market Overview 72 Market Revenue 73 TABLE 8 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 31 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, ($ MILLIONS)
5 TOFACITINIB (CP-690,550)-JANUS KINASE (JAK) INHIBITOR 74 Market Overview 75 Market Revenue 75 TABLE 9 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS) FIGURE 32 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, ($ MILLIONS) MARKET SHARE 77 TABLE 10 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) FIGURE 33 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) MARKET BY REGION 77 MARKET OVERVIEW 78 MARKET REVENUE 79 TABLE 11 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS) FIGURE 34 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, ($ MILLIONS) MARKET SHARE 80 TABLE 12 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) FIGURE 35 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) PROSPECTIVE FUTURE MARKET FOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) INDUSTRY STRUCTURE 81 MARKET LEADERS 82 TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS MARKET SHARES 83 TABLE 14 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) FIGURE 36 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) MARKET APPLICATIONS 84 TABLE 15 APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES MYELOFIBROSIS 86 RHEUMATOID ARTHRITIS 86 MARKET OVERVIEW 87 MARKET REVENUE 89 TABLE 16 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS) FIGURE 37 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, ($ MILLIONS) MARKET SHARE
6 TABLE 17 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) FIGURE 38 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) PROSPECTIVE APPLICATION OF SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) CANCER 91 INFLAMMATORY DISEASES 92 CARDIAC AILMENTS 92 OTHERS CHAPTER 7 PATENT ANALYSIS 95 PATENTS BY YEAR 96 TABLE 18 TOTAL NUMBER OF PATENTS EACH YEAR, FIGURE 39 TOTAL NUMBER OF PATENTS EACH YEAR, PATENTS BY SIGNAL TRANSDUCTION THERAPIES CATEGORY (JAK AND PI3K) 96 TABLE 19 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, FIGURE 40 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, PATENTS BY SIGNAL TRANSDUCTION THERAPIES TYPE 97 PATENTS BY JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS TABLE 20 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED FIGURE 41 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, PATENTS BY PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS TABLE 21 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 42 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED PATENTS BY COUNTRY 99 JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS 99 TABLE 22 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED FIGURE 43 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED TABLE 23 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) FIGURE 44 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/ INHIBITORS/BIOMARKERS TABLE 24 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 45 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 25 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%)
7 FIGURE 46 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%) PATENTS BY COMPANY 103 JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS 103 TABLE 26 NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/ INHIBITORS/BIOMARKERS TABLE 27 NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED PATENTS BY ASSIGNEE 106 JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS 106 TABLE 28 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED FIGURE 47 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS TABLE 29 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 48 PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED CHAPTER 8 CURRENT SITUATION 110 NEW TECHNOLOGIES AND PLATFORMS IN SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) SCREENING TECHNOLOGY 111 PYRAMID 111 BIOMARKERS 111 FACTORS AFFECTING THE SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET CURRENT DRIVERS OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET COLLABORATIONS/ACQUISITIONS 113 TABLE 30 FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) CHAPTER 9 COMPANY PROFILES 117 ABBVIE INC. 117 AETERNA ZENTARIS INC. 117 AMGEN INC 119 ASTELLAS PHARMA INC. 119 ASTEX PHARMACEUTICALS INC 120 ASTRAZENECA PLC 121 BAYER HEALTHCARE PHARMACEUTICALS 121 CELL THERAPEUTICS INC 122 CURIS INC. 124 DAIICHI SANKYO CO. LTD 124 ELI LILLY AND CO. 125 EXELIXIS INC. 126
8 GALAPAGOS NV 126 GENENTECH INC 128 GILEAD SCIENCES INC. 128 GLAXOSMITHKLINE 129 INCYTE CORP. 130 INFINITY PHARMACEUTICALS INC. 132 ITALFARMACO S.P.A. 133 JANSSEN BIOTECH INC. 134 MEI PHARMA INC. 134 MERCK & CO. INC. 135 MILLENNIUM 135 NATIONAL CANCER INSTITUTE 136 NIPPON ZENYAKU KOGYO CO., LTD. 137 NOVARTIS INTERNATIONAL AG 138 NS PHARMA, INC 139 ONCOTHYREON INC 139 PATHWAY THERAPEUTICS LTD 140 PFIZER 141 PIRAMAL ENTERPRISES LIMITED 142 PORTOLA PHARMACEUTICALS INC 142 RIGEL PHARMACEUTICALS INC. 143 SANOFI ONCOLOGY 144 TEVA PHARMACEUTICALS INDUSTRIES LTD 145 TG THERAPEUTICS INC. 146 VERASTEM INC. 146 VERTEX PHARMACEUTICALS INC 147 WILEX AG 148 XCOVERY HOLDING COMPANY, LLC 148 CHAPTER 10 APPENDIX I-ABBREVIATIONS 151
9 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS) TABLE 1 CLASSIFICATION OF JANUS KINASE (JAK) 13 TABLE 2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K) 14 TABLE 3 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS TABLE 6 NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY TABLE 7 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS) TABLE 8 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 9 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS) TABLE 10 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) TABLE 11 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS) TABLE 12 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS TABLE 14 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) TABLE 15 APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES TABLE 16 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS) TABLE 17 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) TABLE 18 TOTAL NUMBER OF PATENTS EACH YEAR, TABLE 19 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, TABLE 20 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED TABLE 21 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 22 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED TABLE 23 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) TABLE 24 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 25 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%)
10 TABLE HEADING TABLE 26 NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED TABLE 27 NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 28 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED TABLE 29 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED TABLE 30 FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)
11 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), ) ($ MILLIONS) FIGURE 1 STRUCTURE OF INC424 (RUXOLITINIB) 15 FIGURE 2 STRUCTURE OF CP-690,550 (TOFACITINIB) 16 FIGURE 3 STRUCTURE OF BARICITINIB (INC28050/LY ) 16 FIGURE 4 STRUCTURE OF MOMELOTINIB (CYT-387) 17 FIGURE 5 STRUCTURE OF AT FIGURE 6 STRUCTURE OF PACRITINIB (SB1518) 18 FIGURE 7 STRUCTURE OF LY FIGURE 8 STRUCTURE OF TG (SAR302503) 19 FIGURE 9 STRUCTURE OF BMS FIGURE 10 STRUCTURE OF LESTAURTINIB (CEP-701) 20 FIGURE 11 STRUCTURE OF WP FIGURE 12 STRUCTURE OF AG FIGURE 13 STRUCTURE OF AZD FIGURE 14 STRUCTURE OF WORTMANNIN 24 FIGURE 15 STRUCTURE OF PERIFOSINE (KRX-0401) 25 FIGURE 16 STRUCTURE OF LY FIGURE 17 STRUCTURE OF IDELALISIB (GS-1101, CAL-101) 26 FIGURE 18 STRUCTURE OF PX FIGURE 19 STRUCTURE OF IPI FIGURE 20 STRUCTURE OF BKM FIGURE 21 STRUCTURE OF COPANLISIB (BAY ) 29 FIGURE 22 STRUCTURE OF PF (PKI-587) 30 FIGURE 23 STRUCTURE OF PICTILISIB (GDC-0941) 30 FIGURE 24 STRUCTURE OF DACTOLISIB (BEZ235) 31 FIGURE 25 STRUCTURE OF APITOLISIB (GDC-0980) 31 FIGURE 26 STRUCTURE OF ZSTK FIGURE 27 STRUCTURE OF SAR (XL765) 33 FIGURE 28 STRUCTURE OF APITOLISIB SAR (XL147) 33 FIGURE 29 STRUCTURE OF APITOLISIB BYL FIGURE 30 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, FIGURE 31 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, ($ MILLIONS) FIGURE 32 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, ($ MILLIONS) FIGURE 33 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%) FIGURE 34 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, ($ MILLIONS) FIGURE 35 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS) FIGURE 36 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%) FIGURE 37 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, ($ MILLIONS)
12 FIGURE TITLE FIGURE 38 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%) FIGURE 39 TOTAL NUMBER OF PATENTS EACH YEAR, FIGURE 40 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, FIGURE 41 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, FIGURE 42 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 43 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED FIGURE 44 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED (%) FIGURE 45 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED FIGURE 46 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED (%) FIGURE 47 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED FIGURE 48 PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED
CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationREGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationBOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationVaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationContraceptives: Technologies and Global Markets
A BCC Research Healthcare Report HLC085A Use this report to: Learn how shifting demographic and sociological factors such as population growth, proportion of young population, and perceptions about family
More informationINTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationTHYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
More informationTHERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE
THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE PHM125A January 2013 Willem Westra Project Analyst ISBN: 0-89336-715-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,
More informationMEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationLIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS
LIQUID BIOPSY RESEARCH TOOLS, SERVICES AND DIAGNOSTICS: GLOBAL MARKETS BIO150A January 2016 John Bergin Project Analyst ISBN: 1-62296-224-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationNUTRACEUTICALS: GLOBAL MARKETS
NUTRACEUTICALS: GLOBAL MARKETS FOD013E November 2014 Natraj Pandal Project Analyst ISBN: 1-56965-992-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the
More informationExecutive Summary. Reproduction prohibited v
Kinases are a large family of proteins that have now become firmly established as a major class of drug targets for the pharmaceutical industry. The sequencing of the Human Genome has led to the identification
More informationDNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS BIO067B July 2014 Jon Evans Project Analyst ISBN: 1-56965-883-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationSickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS
ORGANIC FOODS AND BEVERAGES: GLOBAL MARKETS FOD067A June 2014 Natraj Pandal Project Analyst ISBN: 1-56965-851-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationRENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
RENAL BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS BIO138A January 2015 Cheng-Yuk Lee Project Analyst ISBN: 1-62296-003-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 024 USA 866-285-7215 (toll-free
More informationGlobal Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
More informationDAVAOncology, LP...facilitating successful drug development
DAVAOncology, L Tyrosine Receptor Kinase I3K p85 p110 TEN TORC1 RAS I2 I3 Efficacy of targeted therapy is challenged by the complexity of tumor biology, including cross talk and redundancies between divergent
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationU.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE
U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE FOD029E January 2015 Mary Anne Crandall Project Analyst ISBN: 1-62296-005-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS. HLC167A February Vijay Laxmi Project Analyst ISBN:
ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS HLC167A February 2014 Vijay Laxmi Project Analyst ISBN: 1-56965-704-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationRADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS
RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS HLC176A February 2015 Neha Maliwal Project Analyst ISBN: 1-62296-043-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationPHM029D - Antifungal Drugs: Technologies and Global Markets TABLE OF CONTENTS
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 INTENDED AUDIENCE 2 SCOPE OF REPORT 2 METHODOLOGY 2 INFORMATION SOURCES 2 ANALYST CREDENTIALS 3 RELATED
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationClinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
More informationPI3K. 1
PI3K PI3K (Phosphatidylinositol-4,5-bisphosphate 3-kinase) are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationGLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationOrencia (Rheumatoid Arthritis)
Orencia (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1006DFR / Published November 2012 Executive Summary Orencia: Key Metrics in Rheumatoid Arthritis Markets 2012 Orencia Sales Total 7 MM $831m
More informationActemra (Rheumatoid Arthritis)
Actemra (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1007DFR / Published November 2012 Executive Summary Actemra: Key Metrics in Rheumatoid Arthritis Markets 2012 Actemra Sales Total 7 MM $355m
More informationTABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
More informationTHERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER. HLC143A June Usha Nagavarapu Project Analyst ISBN: X
THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER HLC143A June 2013 Usha Nagavarapu Project Analyst ISBN: 1-56965-431-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationGlobal Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage
Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)
More informationMICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES
MICROELECTRONIC MEDICAL IMPLANTS: PRODUCTS, TECHNOLOGIES & OPPORTUNITIES HLC016E May 2016 Andrew McWilliams Project Analyst ISBN: 1-62296-295-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationRituxan (Rheumatoid Arthritis)
Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1008DFR / Published November 2012 Executive Summary Rituxan: Key Metrics in Rheumatoid Arthritis Markets 2012 Rituxan Sales Total 7 MM $835m
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationBIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS
BIOPSY DEVICES: TECHNOLOGY AND GLOBAL MARKETS HLC171B March 2016 Yojana Jeevane Project Analyst ISBN: 1-62296-257-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationJakinibs 101: Theory, Practice and Prospects. References 10/27/2013
Jakinibs 101: Theory, Practice and Prospects As a rheumatologist, what do you need to know? Why should you care? Understand what Jaks are Which cytokines care, which don t Mechanisms underlying Jakinib
More informationHIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
More informationOVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS
OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS PHM050B February 2014 Anand Gijare Project Analyst ISBN: 1-56965-690-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationREFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationREFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Mavrilimumab in the 10MM Rheumatoid Arthritis
More informationU.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,
More informationCOPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
More informationCHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationREFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Sarilumab in the 10MM Rheumatoid Arthritis (RA)
More informationAtrial Fibrillation - Pipeline Review, H1 2017
Report Information More information from: https://www.wiseguyreports.com/reports/1095866-atrial-fibrillation-pipeline-review-h1-2017 Atrial Fibrillation - Pipeline Review, H1 2017 Report / Search Code:
More informationFor personal use only
ASX RELEASE 10 January 2018 KAZIA PRESENTATION TO BIOTECH SHOWCASE Sydney, 10 January 2018 Australian oncology-focused biotechnology company Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is pleased
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
More informationCHAPTER FOUR: MARKET SIZE AND GROWTH SLEEP MEDICATIONS MARKET PRESCRIPTION... 40
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 BCC
More informationThe Role of Pharmaceutical Industry in Vaccine R&D
The Role of Pharmaceutical Industry in Vaccine R&D Jean-Paul Prieels 12/03/13 1 The Players : 5 majors share over 90% of the global vaccine market 2 new entrants : J&J (Crucell) and Takeda 12/03/13 2 Where
More informationIncyte Corporation. Hervé Hoppenot President & CEO. 34th J.P. Morgan Annual Healthcare Conference January 11, 2016
Incyte Corporation Hervé Hoppenot President & CEO 34th J.P. Morgan Annual Healthcare Conference January 11, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters
More informationOncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
More information(Incidence, Treatments, Key Companies, Pipeline and Trends)
World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends) CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and
More informationREFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Xeljanz (tofacitinib) in the 10MM
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationREFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Orencia (abatacept) in the 10MM (US,
More informationGlobal Rheumatoid Arthritis Market: Trends and Opportunities ( )
Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) Global Rheumatoid Arthritis Market Report Scope of the report The report titled Global Rheumatoid Arthritis Market: Trends and Opportunities
More informationVisceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research
Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research The global visceral pain market size was estimated at USD 9.51 billion in 2016 and is expected to
More informationPancreatic Cancer Market Research Report- Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationCognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Cognitive Impairment Associated
More informationCHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationTABLE 4 U.S. TEETH CLEANING VISITS BY SELECTED CHARACTERISTICS (%) TABLE 4 (CONTINUED) FIGURE 2 U.S. POPULATION WITH TEETH CLEANING
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 2 ANALYST... 3 RELATED BCC STUDIES... 3 BCC ONLINE SERVICES... 3 DISCLAIMER...
More informationOrgan Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC498DFR PUBLICATION DATE DECEM BER 2014 ACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Actemra/RoActemra (tocilizumab)
More informationREFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Cimzia (certolizumab pegol)
More informationOperatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC ON-LINE SERVICES...
More informationGRNVAC DCVax-Brain AGS Glionix CYT004-MelQbG CDX-110 (PF ) GI TABLE 23 OCCURRENCE OF
CHAPTER ONE: INTRODUCTION.1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 3 AUTHOR S CREDENTIALS...
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationREFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Iguratimod/T-614 in the 10MM (US, France,
More informationREFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered
More informationIncyte Corporation. Q Financial and Corporate Update August 9, 2016
Incyte Corporation Q2 2016 Financial and Corporate Update August 9, 2016 Speakers Hervé Hoppenot Chief Executive Officer David Gryska Chief Financial Officer Barry Flannelly General Manager, U.S. Reid
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationGLYCOBIOLOGY: GLOBAL MARKETS FOR DIAGNOSTICS AND THERAPEUTICS
GLYCOBIOLOGY: GLOBAL MARKETS FOR DIAGNOSTICS AND THERAPEUTICS BIO153A September 2016 Marianna Tcherpakov Project Analyst ISBN: 1-62296-358-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationLonasen (Blonanserin) Lullan (Perospirone) Saphris/Sycrest (Asenapine, ORG 5222, SCH ) Saphris/Sycrest (Continued)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationADULT ENTERAL NUTRITION PARENTERAL NUTRITION U.S. REGULATORY ENVIRONMENT THE INFANT FORMULA ACT OF The 1986 Amendments
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS...
More informationKaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013
Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationDevelopment of Novel Anti-Calcineurin Drugs for the
XI Encuentro de Cooperación Farma-Biotech Development of Novel Anti-Calcineurin Drugs for the Treatment of Inflammatory a Autoimmune Diseases Prof. Juan Miguel Redoo Vascular Biology a Inflammation Department
More informationVascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
More information